The Russian delegation led by President Vladimir Putin will go to China on an official visit. One of the primary objectives of the trip is to finalize an agreement for the establishment of a Russian-Chinese enterprise dedicated to the production of innovative medicines. According to Kirill Dmitriev, the CEO of the Russian Direct Investment Fund, the project is expected to demand a minimum investment of 3 billion rubles.
“The focus will be on replacing some medicines based on Chinese components, transferring Chinese technologies. This will also make it possible to localize drugs and developments with access to the full production cycle of drugs,” he clarified.
The portfolio of drugs produced will be determined based on the results of an analysis of the most popular areas of therapy. According to the agreements reached, National Research Center for Epidemiology and Microbiology named after N.F. Gamaleya will be able to open a research and development center in China, which will allow local adaptation of drugs and additional necessary research.
“Safe and effective Russian drugs have withstood competition from the giants of the pharmaceutical industry and have not demonstrated serious adverse events, and have won the trust of specialists and ordinary people. The partnership between RDIF and OncoGenerix opens up the opportunity to bring other developments of the Gamaleya Center to the Chinese market, which have already proven themselves in Russia and have significant export potential,” Dmitriev said.